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Introduction
The vast majority of clinically used therapies for cancer capital-
ize on differences in the rate of cell replication between tumor-
al and nontumoral cells. In general, therapeutic agents distrib-
ute through the whole body, which results in general toxicity,
a suboptimal concentration of the therapeutic agent in the
tumor and poor therapeutic response.[1] Therefore, in order to
improve cancer treatments, it is necessary to optimize the de-
livery and biodistribution of drugs to diseased organs, tissues
or cells, by devising therapeutic formulations that allow in-
creased localized concentrations of the therapeutic agents in
the target tissues for longer time periods.
Most solid tumors possess defective vascular architecture, in-
creased vascular permeability and leaky vessels. The enhanced
permeability and retention (EPR) effect allows the passage and
distribution of micro/nanoparticulate devices, offering thera-
peutic windows for the delivery of drug substances. To take
advantage of these defects in tumor vasculature, drugs have
been linked to macromolecular structures, polymers or micro/
nanocarriers as vectors.[2–7] However, the retention time in dis-
eased tissue is generally low. Therefore, it is imperative that
nanoparticulate drug carriers are capable of residing in defined
locations for longer periods of time, while releasing therapeu-
tic agents in the appropriate environment at the requisite rate
and dose.
Sustained and elevated tissue concentrations were achieved
with intra-articularly administered ultrasmall superparamagnet-
ic iron oxide nanoparticles (USPIOs) when an external magnet
was applied on the joint.[8] Colloidal dispersions of USPIOs add
a unique function to nanoparticles due to their magnetic prop-
erties.[9–12] A strategically interesting way to achieve site-selec-
tive delivery is by chemical attachment of therapeutic agents
to USPIOs via a cell-specific labile linkage, and steering the
drug–USPIO assembly to specific diseased areas in the body
under the influence of an external magnetic field. This implies
that the drug–nanoparticle assembly must be internalized by
cells, that this uptake be enhanced by an external magnetic
field, and subsequently, that the drug be released intracellular-
ly to exert its expected therapeutic effects.
The design, preparation and evaluation of magnetic nano-
particles displaying drugs at their surface are only in their early
phase of development.[7] Creating the toolbox of anticancer
molecules that can be hierarchically assembled into an or-
dered, spatially and chemically defined architecture at the sur-
face of magnetically active nanoparticles is a major synthetic
challenge. The attachment of drugs to biocompatible USPIOs
through ester linkages that can be cleaved by esterases once
inside a cancer cell would offer a possible solution to selective
drug delivery.[13] The potential of drug delivery based on mag-
netically activated nanoparticles has been evaluated in vivo
The linking of therapeutic drugs to ultrasmall superparamag-
netic iron oxide nanoparticles (USPIOs) allowing intracellular re-
lease of the active drug via cell-specific mechanisms would
achieve tumor-selective magnetically-enhanced drug delivery.
To validate this concept, we covalently attached the anticancer
drug camptothecin (CPT) to biocompatible USPIOs (iron oxide
core, 9–10 nm; hydrodynamic diameter, 52 nm) coated with
polyvinylalcohol/polyvinylamine (PVA/aminoPVA). A bifunction-
al, end-differentiated dicarboxylic acid linker allowed the at-
tachment of CPT to the aminoPVA as a biologically labile ester
substrate for cellular esterases at one end, and as an amide at
the other end. These CPT–USPIO conjugates exhibited antipro-
liferative activity in vitro against human melanoma cells. The
intracellular localization of CPT–USPIOs was confirmed by
transmission electron microscopy (iron oxide core), suggesting
localization in lipid vesicles, and by fluorescence microscopy
(CPT). An external static magnetic field applied during expo-
sure increased melanoma cell uptake of the CPT–USPIOs.
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with significant advantages, in-
cluding the possibility of achiev-
ing targeted delivery and de-
creased off-target effects.[14–20]
For example, the covalent at-
tachment of methotrexate at the
surface of USPIOs and its release
in vivo by lysosomal proteases
has led to a study of its thera-
peutic potential.[21–23] However,
to the best of our knowledge,
the attachment and delivery of
ester-linked anticancer agents to
USPIOs has not been exploited
successfully.
The plant alkaloid camptothe-
cin (CPT) and its analogues are
specific inhibitors of the nuclear
DNA topoisomerase I,[24,25] and
are active as cytostatic drugs
against many solid tumors, in-
cluding melanoma.[26] To im-
prove the low solubility of CPT, chemical modifications, conju-
gation to polymers, intercalation into liposomes, solubilization
in microemulsions, and entrapment in microspheres and micel-
lar colloidal particles have been studied.[27,28]
We have previously reported the preparation and characteri-
zation of various USPIOs coated with polyvinylalcohol/polyvi-
nylamine mixtures, which were internalized by nonphagocytic
human tumor cells.[29–31] Bifunctional linkers to which the anti-
cancer drugs doxorubicin or 5-fluorouridine were attached by
either amide or ester linkages were also previously reported.[32]
In the present work, we studied the efficacy of the potent anti-
cancer agent CPT attached as an ester to an amide-linked bi-
functional spacer to aminoPVA polymers containing USPIOs.
Herein, we report the uptake of such CPT–USPIO conjugates,
their effect on cells, and the potential utility of an external
magnet to enhance their uptake in human melanoma cancer
cells.
Results and Discussion
Chemistry
Firstly, CPT was covalently attached via its hydroxyl group at
position 20 to the aminoPVA polymer through an end-differen-
tiated azido dicarboxylic acid linker 1.[32] This linker contains
two carboxylic acid groups, which were used for attachment of
CPT at one end, and coupling to the aminoPVA at the other,
prior to addition of the ferrofluid to formulate the final CPT–
USPIOs 4 (Scheme 1). Esterification of the tertiary alcohol of
CPT was done in the presence of EDC and DMAP. Cleavage of
the Me3Si ethyl ester gave the carboxylic acid 2, which was
coupled with aminoPVA in aqueous DMF to give the CPT–
linker conjugate 3. The product was purified by dialysis and re-
sidual free drug was removed from a lyophilized white solid by
repeated trituration with CH2Cl2. In order to quantify the
amount of drug linked to the polymer, an azide group was in-
corporated in the linker to calculate the ratio of the area under
the azide peak at 2100 cm1 to that of a reference peak in the
aminoPVA at 1100 cm1 in the IR spectra of coupled products,
as previously described.[32] This method demonstrated that
24% of the amino groups of the aminoPVA were substituted
by CPT.
Preparation and characterization of CPT–USPIOs 4
Superparamagnetic iron oxide nanoparticles (9 nm iron oxide
core, ferrofluid) were prepared by alkaline coprecipitation of
ferric and ferrous salts, as previously described.[29–31] The CPT–
USPIO conjugate 4 was prepared by adding the ferrofluid to
mixtures of PVA/aminoPVA/CPT–linker–aminoPVA 3 to obtain
homogeneous amber-brown colored solutions. We previously
showed that USPIO conjugates coated with PVA/aminoPVA at
a ratio of 45:1 (w/w) and a polymer/iron ratio of 10:1 (w/w),
with a defined positivity, are biocompatible and efficiently
taken up by cells.[29–31] Therefore, a constant ratio of total poly-
mer to iron of 10 was maintained, and the positively charged
surface of CPT–USPIO conjugate 4 was maintained by compen-
sating for the loss of the amino groups of the aminoPVA (due
to drug substitution) by increasing the ratio of aminoPVA to
PVA during coating of the ferrofluid (Table 1).
The hydrodynamic size and surface charge determined by
photon correlation spectroscopy (PCS), electrophoretic mobili-
ties (charge/size ratio) and zeta (z) potential of the CPT–USPIO
conjugate 4 and the model aminoPVA-USPIOs[30] were very
comparable (Table 2). The physicochemical characteristics of
CPT–USPIO conjugate 4 were consistent with their expected
composition. CPT–USPIO conjugate 4 had comparable particle
size and size distribution to aminoPVA-USPIOs as measured by
PCS, but slightly lower charge positivity.
Scheme 1. Reagents and conditions : a) camptothecin, EDC, DMAP, CH2Cl2, RT, o/n; b) TFA/CH2Cl2 (1:1), RT, 40 min;
c) EDC, HOBt, aminoPVA, DMF/H2O, RT, 1 d; d) ferrofluid.
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Cellular assays
The human Me300 melanoma
cells were selected from a panel
of human cancer cells for their
high uptake of aminoPVA-USPIO
and CPT–USPIO. To evaluate the
stability of the CPT–USPIO conju-
gate 4 at physiological pH, gel
filtration was performed at pH 7,
and the elution profile of iron
and PVA was compared to the
fluorescence associated with CPT
(Figure 1). The CPT–USPIO conju-
gate 4 eluted as a major single
high molecular weight fraction
encompassing iron, PVA and CPT
(Figure 1a). The gel filtration
fractions were evaluated for bio-
logical activity and revealed that
a peak corresponding to a major
high molecular weight compo-
nent, combining CPT, the PVA
polymer and iron, corresponding
to CPT–USPIO conjugate 4, effi-
ciently decreased DNA synthesis
in melanoma cells (Figure 1a,
insert).
A minor, iron-negative and
PVA-negative, lower molecular
weight peak exhibited some effi-
cacy in inhibiting DNA synthesis
in melanoma cells (Figure 1a,
insert), suggesting only minimal
hydrolytic release of CPT from
the carrier at this pH over time,
which alone can not account for
the observed effects. AminoPVA-USPIOs had no effect on DNA
synthesis in melanoma cells (results not shown). In order to de-
termine whether the bulky structure of CPT–USPIO conjugate
4 could be a substrate for melanoma cell esterases, it was ex-
posed to human Me300 melanoma cell extracts and the specif-
ic CPT fluorescence, as well as iron and PVA, were evaluated by
gel-filtration (Figure 1b). The results clearly demonstrated an
important increase in free CPT
fluorescence in the low molecu-
lar weight fractions, providing
evidence that the ester bond
linking CPT to the USPIOs via
the linker was accessible to cel-
lular esterases of human melano-
ma cells, and that these esteras-
es have the potential to release
the drug from the nanoparticle–
linker carrier, despite the bulky
structure of the conjugate.
Table 1. Quantitative composition determination of the CPT–USPIOs 4.[a]
CPT–aminoPVA
ACHTUNGTRENNUNG[%, w/v]
PVA
ACHTUNGTRENNUNG[%, w/v]
aminoPVA
ACHTUNGTRENNUNG[%, w/v]
Iron
ACHTUNGTRENNUNG[%, w/v]
CPT
[mm]
CPT–USPIOs 4 0.8 37.5 0.2 3.8 357
[a] The substitution by CPT of the amino groups of the aminoPVA repre-
sented 24% of the total number of amino groups.
Table 2. Size, amino group concentration, electrophoretic mobility and z-potential of the amino-USPIOs and
CPT–USPIOs 4.
Size[a]
[nm]
Free amino groups[b]
[mm]
Mobility
[108 ms1V1m]
z-potential
[mV]
aminoPVA-USPIOs 56.44.1 1.59 1.330.04 17.00.5
CPT–USPIOs 4 52.17.7 1.49 0.420.13 6.41.3
[a] Nanoparticle hydrodynamic diameter. [b] Residual free amino groups on the aminoPVA were calculated
from the known number (2.5% N, w/w) of amino groups in unfunctionalized aminoPVA and the number of
bound CPT per aminoPVA.
Figure 1. The CPT–USPIOs were gel filtrated on Sephadex G-75 in PBS at pH 7. Iron and PVA were quantified at
690 nm by Prussian blue and iodine reactions, respectively, and camptothecin (CPT) by fluorescence in H2O at lex/
lem of 360/460 nm. a) Gel filtration of CPT–USPIOs 4 ; Iron (&) ; PVA (^) ; CPT (~). Insert : biological activity of the gel
filtration fractions evaluated by inhibition of DNA synthesis in human Me300 melanoma cells (3HT incorporation
[cpm]) (*). b) Evaluation by gel filtration of the release of CPT from CPT–USPIOs 4 pre-incubated for 24 h at 37 8C
with PBS extract of Me300 cells. Iron (&) ; PVA (^) ; CPT (~).
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The amount of CPT–USPIO conjugate 4 taken up by human
Me300 melanoma cells after 16 h and 36 h as a function of the
number of nanoparticles added was determined by the
amount of cell-associated iron and cell-associated CPT fluores-
cence (Figure 2a and b, inserts) as compared with that of the
previously described aminoPVA-USPIOs.[30] After 16 h, the
uptake of aminoPVA-USPIOs and CPT–USPIO conjugate 4 was
comparable (Figure 2a). However, after 36 h, uptake of cyto-
toxic conjugate 4 continued to increase in the still-surviving
cells, whereas the uptake of noncytotoxic aminoPVA-USPIOs
had ceased due to saturation (Figure 2b). Histological determi-
nation of cell-associated iron (Figure 2c) and CPT fluorescence
(Figure 2d) showed incorporation of CPT–USPIO conjugate 4 in
the melanoma cells. The intracellular localization of the iron
oxide core of the conjugate 4 in cell organelles was further
demonstrated by transmission electron microscopy (TEM) (Fig-
ure 2e). The appearance of the vesicles was suggestive of lipid
vesicles. In order to confirm the localization of CPT–USPIO 4 in
melanoma cells, histological staining for lipids (Figure 3a
and b), TEM imaging (Figure 3c) and elemental analysis of
USPIO containing granules (Figure 3d) were performed, strong-
ly suggesting localization of CPT–USPIO in lipid vesicles.
Figure 2. Human Me300 melanoma cells were exposed for a) 16 h or b) 36 h to increasing concentrations of the CPT–USPIOs 4 or aminoPVA-USPIOs and cell
iron content was determined. CPT–USPIOs 4 (&) ; aminoPVA-USPIOs (). The uptake by cells of CPT associated to the USPIOs was determined by its specific
cell-associated fluorescence in the intact cell layer (&, inserts). The uptake of CPT–USPIOs (0.7 mm CPT in CPT–USPIOs, 8 mg FemL1) after 36 h was also exam-
ined in parallel cultures of Me300 cells grown on histological slides: c) histological Prussian blue reaction; d) CPT cell-associated characteristic fluorescence;
and e) transmission electron microscopy (TEM) demonstrating the iron oxide core of the CPT–USPIOs in intracellular organelles (%).
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The effect of CPT–USPIO con-
jugate 4, compared with free
CPT, on the survival of human
melanoma cells was evaluated
using the Alamar Blue reaction
and DNA synthesis (Figure 4).
The effect of free CPT either on
DNA synthesis or cell survival
was already apparent after 16 h
exposure (Figure 4a) and was
enhanced after 36 h (Figure 4b).
As expected for this type of anti-
cancer agent, inhibition of DNA
synthesis preceded decrease in
cell survival, which was apparent
only after 36 h of exposure (Fig-
ure 4b). The time dependency of
antiproliferative activity of CPT–
USPIO conjugate 4 was slower
than that of free CPT.
Due to the superparamagnetic
properties of USPIOs, we expect-
ed the local concentration at the
cell surface and/or uptake by
cells of CPT–USPIO conjugate 4,
compared to free CPT, to be en-
hanced by applying an external
magnetic field. An experimental
system was devised consisting
of a 48-well plate whose wells
were filled with round static
magnets and inserted under a
similar 48-well plate containing
the human melanoma cells (Fig-
Figure 3. Human Me300 melanoma cells were exposed to CPT–USPIOs (8 mg FemL1, 0.7 mm CPT) for 36 h, and
a) stained by Sudan for lipid visualization (brownish spots, see b) for magnification) or c) examined by TEM imag-
ing. d) Elemental analysis of iron was also performed.
Figure 4. Human Me300 melanoma cells were exposed for a) 16 h or b) 36 h to increasing concentrations of CPT or the CPT–USPIOs 4 and either cell survival
(Alamar Blue reduction, AlaB) or DNA synthesis ([3H]-thymidine incorporation, 3HT) were determined. CPT–USPIOs 4 (AlaB) (^, g) ; CPT–USPIOs 4 (3HT) (^,
c) ; free CPT (AlaB) (~, g) ; free CPT (3HT) (~, c).
992 www.chemmedchem.org  2009 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2009, 4, 988 – 997
MED S. Hanessian, L. Juillerat-Jeanneret, et al.
ure 5a). The loss of the magnetic field as a function of the dis-
tance to the magnet was calculated (Figure 5b). Under the ex-
perimental conditions, the cell layer was exposed to a 265 mT
magnetic field that decreased almost linearly to reach less
than 100 mT at the surface of the cell culture medium. The re-
sults clearly demonstrated that exposure to the magnetic field
increased the binding of the conjugate 4 to human melanoma
cells as measured by cell-associated iron (not shown) and CPT
fluorescence (Figure 6a). Thus, the superparamagnetic proper-
ties of drug–USPIOs with an iron oxide core of ~10 nm in-
creased cell-associated iron and drug content. However,
whereas the magnetic field increased cell content of the conju-
gate 4, the time-dependent antiproliferative effect of the con-
jugate was not increased (Figure 6b and c). This information
strongly suggests that the limiting rate for antiproliferative effi-
cacy is not the uptake of these drug–USPIOs by cells, but the
release of the drug from its nanoparticulate carrier via an ester-
olytic step, and its diffusion out of the cell organelle(s) and
into the cell nucleus.
Conclusions
In summary, a viable synthetic route to USPIOs containing a
polymer, a linker and a covalently linked anticancer drug (CPT)
have been examined in this study. We demonstrated that a hi-
erarchical building of a covalent drug–USPIO assembly is possi-
ble, even for highly hydrophobic drugs like CPT. The uptake of
the CPT–USPIOs by human melanoma cells resulted in de-
creased cell survival as estimated from the decrease in meta-
bolic activity and DNA synthesis after long-term exposure. The
exposure of the melanoma cell layer to a permanent static
magnet increased the amount of cell-associated CPT–USPIOs in
melanoma cells, suggesting that the same effect could be ach-
ieved in vivo. However, the rate-limiting step for therapeutic
efficacy is the bioprocessing of these superparamagnetic vec-
tors by cellular mechanisms. The cell uptake mechanisms, the
accessibility of the conjugate to esterolytic enzymes for drug
release, and the intracellular routing of these CPT–USPIO as-
semblies are of utmost importance and must be collectively
considered for efficient drug delivery. Further studies in this
fascinating area of magnetically-directed drug delivery are
under active investigation and will be reported in due course.
Experimental Section
Chemistry
General
All commercially available reagents were used without further pu-
rification. All reactions were performed under nitrogen atmos-
phere. NMR (1H, 13C) spectra were recorded on Bruker ARX-400, AV-
300 and AV-400 RG spectrometers. Low- and high-resolution mass
spectra were recorded using electrospray technique. Optical rota-
tions were recorded on a Perkin–Elmer Model 343 polarimeter in a
1 dm cell at room temperature. Analytical TLC was performed on
precoated silica gel plates. Flash column chromatography was per-
formed using (40–63 mm) silica gel. IR was measured on a Perkin–
Elmer Spectrum One FT-IR spectrometer. IR spectra of organic com-
pounds were taken as films, while of polymer mixtures were taken
after an aqueous polymer sample was mixed with KBr and lyophi-
lized to give a fine powder that was pressed into a disk.
Nanoparticle synthesis
[2-Azidomethyl-3-(4-ethyl-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-
oxa-6,12a-diaza-dibenzo ACHTUNGTRENNUNG[b,h]fluoren-4-yloxycarbonylmethoxy)-2-
methyl-propoxy]-acetic acid (2): The synthesis and characteriza-
tion of 1 has been previously described.[32] A solution of 1 (0.093 g,
0.26 mmol) in CH2Cl2 (3.5 mL) was treated with camptothecin
(0.060 g, 0.17 mmol), DMAP (0.015 g, 0.12 mmol) and EDC (0.132 g,
0.69 mmol) and the reaction mixture was stirred overnight at RT.
The solvent was evaporated and the residue was purified by
column chromatography (CHCl3/MeOH, 100:0!99:1) to give the
coupled product as a yellow solid (0.109 g, 92%); mp 112–114 8C;
1H NMR (300 MHz, CDCl3): d=8.40 (1H, s), 8.22 (1H, d, J=8.5 Hz),
7.94 (1H, d, J=8.1 Hz), 7.87–7.81 (1H, m), 7.70–7.65 (1H, m), 7.21
(1H, d, J=1.3 Hz), 5.67 (1H, d, J=17.2 Hz), 5.39 (1H, d, J=17.2 Hz),
5.29 (2H, s), 4.34–4.16 (4H, m), 4.10–3.98 (2H, m), 3.46–3.30 (6H,
m), 2.36–2.11 (2H, m), 1.04–0.94 (8H, m), 0.04–0.01 ppm (9H, m);
13C NMR (75 MHz, CDCl3): d=170.5, 169.5, 167.3, 157.3, 152.3,
148.9, 146.5, 145.5, 131.3, 130.8, 129.6, 128.5, 128.3, 128.2, 128.1,
120.3, 95.9, 76.4, 74.5, 74.1, 68.8, 68.4, 67.2, 63.1, 55.2, 50.0, 41.1,
31.9, 17.8, 17.4, 7.6, 1.5 ppm; IR (neat/NaCl): n˜=2950, 2102, 1755,
1672, 1623, 1128 cm1; LRMS (ESI): m/z [MH]+ 692.
Figure 5. Experimental setting: magnetic flux density [mT] as a function of
the distance to the magnet surface [mm]. Magnet (0 mm): 424 mT; cell layer
(2.8 mm): 212 mT; upper level of the CPT–USPIOs solution in the culture
wells (6 mm): 85 mT.
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The ester (0.109 g, 0.16 mmol) was dissolved in TFA/CH2Cl2 (1:1,
6 mL) and stirred at RT for 40 min. The solvent was removed in va-
cuo and traces of TFA were removed by co-evaporating with
MeOH. Column chromatography (CH2Cl2/MeOH, 9:1) gave the de-
sired product 2 as an off-white solid (0.082 g, 88%). Warning; CHCl3
or CDCl3 may cause decomposition of this compound ;
1H NMR
(400 MHz, [D6]DMSO): d=8.66 (1H, s), 8.15–8.08 (2H, m), 7.85 (1H,
t, J=7.7 Hz), 7.69 (1H, t, J=7.4 Hz), 7.12 (1H, s), 5.53 (2H, s), 5.26
(2H, s), 4.55–4.27 (2H, m), 3.92 (2H, s), 3.42–3.26 (6H, m), 2.20–2.12
(2H, m), 0.94 (3H, t, J=7.1 Hz), 0.89 ppm (3H, s); 13C NMR
(100 MHz, [D6]DMSO): d=171.7, 169.4, 167.1, 156.5, 152.3, 147.9,
146.1, 145.1, 131.5, 130.4, 129.8, 128.9, 128.5, 128.0, 127.7, 118.8,
94.9, 76.3, 73.9, 73.3, 68.2, 67.9, 66.3, 54.8, 50.2, 40.6, 30.2, 17.5,
7.5 ppm; IR (neat/NaCl): n˜=3400, 2931, 2102, 1755, 1661, 1615,
1129 cm1; LRMS; (ESI): m/z [MH]+ 592; HRMS (ESI): m/z
[MH]+ calcd for C29H29N5O9 592.2038, found 592.2029; [MNa]
+ calcd
for C29H29N5O9Na 614.1857, found 614.1832.
Figure 6. a) Human Me300 melanoma cells were grown in 48 well-plates and exposed for 16 h or 36 h to CPT–USPIOs (21 mg FemL1) either in the absence of
or on a permanent static magnet, then CPT uptake by cells was quantified by fluorescence at 360/460 nm. (&): 16 h without magnet; (&): 16 h with magnet;
(~): 36 h without magnet; (~): 16 h with magnet, followed by 20 h without magnet. After exposure with or without a permanent static magnet of human
Me300 melanoma cells to CPT–USPIOs 4, b) cell survival was ascertained by Alamar Blue staining (g) or c) DNA synthesis by melanoma cells was deter-
mined by [3H]-thymidine incorporation (c) performed during the 2 last hours. (&): 16 h without magnet; (&): 16 h with magnet; (~): 36 h without magnet;
(~): 16 h with magnet, followed by 20 h without magnet.
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CPT–linker-aminoPVA (3): A solution of 2 (21.1 mg, 0.0357 mmol),
HOBt (4.8 mg, 0.0357 mmol) and EDC (13.7 mg, 0.0714 mmol) in
DMF (714 mL, final concentration 0.05m) was stirred for 60 min. A
solution of aminoPVA in DMF/H2O (1:1, 2.0 mL, 10 mgmL
1,
2.5% N, w/w, 0.0357 mmol) was added and the reaction solution
adjusted to pH~6.5 with HCl (0.1n) and/or NaOH (0.1n) as
needed. The mixture was stirred at RT for 1 day. After 16 h the so-
lution was adjusted to the pH 6.5 if necessary. The solution was
then dialyzed (Spectra/Por 6 dialysis membrane, MWCO 3500)
against NaCl (0.2n) for 3 days and then against H2O for 2 days
changing the solution twice daily. The dialyzed solution was further
extracted multiple times with CH2Cl2 until TLC analysis (CH2Cl2/
MeOH, 9:1) of the CH2Cl2 extracts was free of spots. Lyophilization
of the crude material gave 3 as a white solid (3.7 mg).
Preparation of CPT–USPIO (4): Superparamagnetic iron oxide
nanoparticles (ferrofluid) were prepared according to previously
described methods.[29–31,33,34] Briefly, ferrofluid was prepared by al-
kaline co-precipitation of FeCl3 (0.086m) and FeCl2 (0.043m) (Fluka,
Buchs, Switzerland). After washing with H2O, the black precipitate
was refluxed in nitric oxide (0.8m)–FeACHTUNGTRENNUNG(NO3)3·9H2O (0.21m) (Fluka)
for 1 h. The reaction was cooled and the brown precipitate dis-
persed in H2O and dialyzed for 2 days against HNO3 (0.01m). This
ferrofluid was mixed with PVA (3–83, Mowiol, 7600 gmol1, courte-
sy of Clariant) and aminoPVA (M12, Erkol, 20000 gmol1, courtesy
of Erkol) as described previously[29,30] to obtain aminoPVA-USPIOs,
and the pH was adjusted to 7.0. For the experiments described
here, the ratio of total polymer to iron was 10 (mass ratios). As pre-
viously described,[30] for aminoPVA-USPIOs the mass ratio of PVA to
aminoPVA copolymer was 45. For the preparation of CPT–USPIOs,
the ferrofluid was mixed in ultrapure H2O with PVA, aminoPVA co-
polymer and CPT–linker–aminoPVA 3 at defined ratios (Table 1),
then the CPT–USPIOs 4 were stabilized at pH 6–7.
Physical characterization of CPT–USPIO 4
Particle sizes were measured by photon correlation spectroscopy
(PCS) using a Brookhaven apparatus equipped with a BI-9000AT
digital autocorrelator instrument and a He-Ne laser beam at a
wavelength of 661 nm (scattering angle of 908). The CONTIN
method was used for data processing. Viscosity and refraction
index of pure water were used for size distribution calculation.
Coated-USPIOs were diluted 51 fold in 0.01m HNO3 in ultra pure
water pre-filtered on 20 nm ceramic filters (Whatman, Anodisc 25).
The same setting equipped with platinum electrodes was used for
electrophoretic mobility measurements and z-potential was calcu-
lated using the Smoluchowski approximation. The electrodes were
cleaned for 5 min in an ultrasonic bath prior to each measurement.
Gel filtration experiments
Samples of 15 mL of CPT–USPIOs were applied to a Sephadex G-75
column (0.619 cm, Pharmacia, Uppsala, Sweden) equilibrated in
NaH2PO4·2H2O (25 mm) and NaCl (0.15m) at pH 7.0, prefiltered
through a 0.22 mm filter (Millex GP, Millipore), at RT with a flow rate
of 20 mLh1. The fractions were analyzed for Fe, PVA and fluores-
cence. For Fe determination, 50 mL of each fraction was mixed with
HCl (50 mL, 6n) for 1 h at RT and a solution of K4[Fe(CN)6·3H2O]
(100 mL, 5%) was added for 30 min. Absorbance was read at
690 nm in a multiwell plate reader (Labsystems iEMS Reader MF,
BioConcepts, Allschwil, Switzerland) and Fe was quantified from a
standard curve of aminoPVA-USPIOs treated under the same condi-
tions. For PVA quantification, 110 mL of distilled water and 70 mL of
a iodine solution (0.45% KI, 0.225% I2 and 3.6% H3BO3 (w/v)) were
added to 20 mL of each fraction and incubated at RT for 30 min.
Absorbance was read at 690 nm in a multiwell plate reader and
the amount of PVA was quantified from a standard curve of PVA
treated under the same conditions. The fluorescence of CPT (in
water) was measured at lex/lem of 360/460 nm in a multiwell plate
reader (CytoFluor, Series 4000, PerSeptive Biosystems).
Cellular assays
Cells and cell treatment : The Me300 human melanoma cell line
(donated by D. Rimoldi, Ludwig Institute, Lausanne, Switzerland)
was grown in RPMI 1640 medium containing 10% fetal calf serum
(FCS) and antibiotics (all from Gibco, Invitrogen, Basel, Switzerland)
at 37 8C and 6% CO2. Two to three days prior to experiments, the
cells were detached with trypsin–EDTA (Gibco), centrifuged and
grown in complete medium in 48-well or 96-well plates (Costar,
Corning, NY, USA), in order to reach 60–80% confluence on the
day of experiment. Fresh complete medium was added prior to ex-
posure to the drugs for the concentration and time indicated.
Stock solutions of (S)-(+)-CPT (Sigma–Aldrich, Buchs, Switzerland)
in DMSO (20 mm) were prepared. DMSO at the same concentration
was used as a control for CPT experiments. Experiments were per-
formed in triplicate wells. [3H]-Thymidine incorporation was mea-
sured to quantify DNA synthesis and Alamar Blue reduction was
used to determine cell viability (see below). Alternatively, the cell
layers were washed twice with saline and cellular iron content was
quantified using the Prussian blue method and drug content by
measuring drug fluorescence (see below).
Evaluation of cell viability and DNA synthesis : To quantify meta-
bolically active cells, 10% Alamar blue (Serotec, Dsseldorf, Germa-
ny) was added to the cell culture medium and fluorescence in-
crease was directly measured in a multiwell fluorescence reader
(lex/lem=530 nm/580 nm) after 2 h at 37 8C. To assess for DNA syn-
thesis, 1 mCimL1 [3H]-thymidine (Amersham Pharmacia, Dben-
dorf, Switzerland), was added for the last 2 h of exposure to com-
pounds and incorporation was quantified in a beta-counter (Rack-
beta, LKB) after precipitation with 10% trichloracetic acid and solu-
bilization in 0.1n NaOH and 1% sodium dodecylsulfate (SDS).
Total cell-bound iron and drug determination : The quantification
of cell-associated nanoparticles was determined by cell iron con-
tent and histological determination of iron by Prussian blue reac-
tion, performed as previously described.[30,31] Briefly, for quantita-
tion of cell iron content, the cell layer was dissolved for 1 h in 6n
HCl (125 mL well1 of a 48-well plate), then 125 mL of a 5% solution
of K4[Fe(CN)6]·3H2O in H2O was added for 20 min and the absorb-
ance was read at 690 nm in a multiwell plate reader. A standard
curve of aminoPVA-USPIOs in 6n HCl was treated in the same con-
ditions to quantify the amount of cell-bound iron and the number
of USPIOs added to or taken up by cells was calculated as previ-
ously described,[26] assuming a mean diameter of the iron oxide
core of 93 nm. Cell-associated drug was determined in lysed
cells by measuring fluorescence intensity in 0.1n NaOH and 1%
SDS at lex/lem of 360 nm/460 nm in a multiwell fluorescence plate
reader. Histological determination of the cell-associated iron and
CPT fluorescence in intact cells was performed on cells grown on
histological slides. Following exposure to CPT–USPIOs 4, the cell
layers were extensively washed in PBS then slides were fixed in
100% cold EtOH for 10 min at 4 8C, dehydrated in graded alcohol
to xylol and mounted. Samples were examined under a fluores-
cence microscope (Axioplan2, Carl Zeiss, AxioCam MRm camera,
AxioVision Rel. 4.6 logiciel, Feldbach, Switzerland) and filter set at
365 nm excitation light (BP 365/12, FT 395, LP 397). Histological
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cell-associated iron determination by Prussian blue reaction was
performed as previously described.[30] Briefly, the cell layer was ex-
posed for 15–30 min at RT to a 1:1 solution of 1n HCl and 2.5%
K4[Fe(CN)6] in H2O, washed with distilled water, counterstained
with nuclear fast red, dehydrated in graded alcohol and mounted.
Histochemical determination of lipids and camptothecin : Cells
were grown on histological slides then exposed to CPT–USPIO 4.
Cell layers were fixed in 70% alcohol and exposed for 2 min to a
Sudan solution (water/EtOH/acetone, 3:7:10; 0.7% (w/v) Sudan III
(Fluka, Buchs, Switzerland), 0.7% (w/v) Sudan IV (BDH Chemicals
Ltd. , Poole, England), sequentially washed in 70% alcohol, tap
water, and counterstained with hematoxylin, then mounted in an
aqueous mounting medium (Immu-mount, Thermo Scientific, Pitts-
burgh, USA). Slides were photographed under a Nikon digital
camera (DXM 1200; Nikon Corporation, Tokyo, Japan).
Enzymatic digestion of CPT–USPIOs 4 and evaluation of drug re-
lease : The release of CPT from CPT–USPIO conjugate 4 was evalu-
ated by harvesting confluent layers of human Me300 melanoma
cells. The cells were scraped from the plates and extracted with
phosphate/NaCl buffer (pH 7.4) by three cycles of freeze-thaw in
liquid nitrogen. Two volumes of CPT–USPIO 4 were exposed for
24 h at 37 8C to one volume of cell extract, centrifuged for 5 min at
1000 rpm, and the supernatant (20 mL) was applied to a Sephadex
G-75 column in phosphate buffer (pH 7), and the eluting fractions
were monitored for iron, PVA and CPT.
Transmission electron microscopy : Me300 cells were grown in
complete medium in a 25 cm2 flask (Nunclon, from Milian, Geneva,
Switzerland) in order to reach 70–80% confluence on the day of
experiment. Fresh complete medium was added prior to exposure
to CPT–USPIOs 4 for the concentration and time indicated. Cells
were washed twice with PBS and 1 mL trypsin/versene (Gibco) was
added for 5 min at 37 8C. Cells were centrifuged (5 min, 1000 rpm)
and the supernatant was removed. The cell pellet was fixed in 2%
glutaraldehyde buffered in 0.05m cacodylate and centrifuged. Cells
were kept in fixative solution for 48 h, then washed three times
with 0.2m cacodylate, postfixed in 1.3% osmium tetroxide in 0.2m
cacodylate for 1 h and dehydrated in graded EtOH, then propylene
oxide. Cell pellets were embedded in epon (50% (w/w) epon 812
substitute, 26% (w/w) dodecenylsuccinic anhydride (DDSA), 23%
(w/w) methylnadic anhydride (MNA), 1% (w/w) 2,4,6-tris(dimethyla-
minomethyl)phenol (DMP-30)). All reagents were purchased from
Fluka. Blocks were cured for 48 h at 60 8C, thin sections (50 nm)
were cut using an ultramicrotome (Ultracut E, Reichert-Jung Opti-
sche Werke AG, Wien, Austria) and mounted on 3 mm 200-mesh
copper grids. Grids were stained using a standard two-step uranyl
acetate/lead citrate (Fluka and Lavrylab, Saint-Fons, France) tech-
nique (Leica EM Stain) and then examined and photographed at
80 kV with a Philips CM10 transmission electron microscope com-
bined with a MegaView III, Soft Imaging system. Elemental analysis
of iron was performed using an electron Detection X-ray (EDAX,
EDX-4), coupled to the CM12 transmission electron microscope.
Magnetic activation of CPT–USPIOs 4 : The cells were detached
with trypsin/versene (Gibco), centrifuged and grown in complete
medium in 48-well plates (Costar) excluding the external wells of
the plate, in order to reach 60–80% confluence on the day of ex-
periment. Fresh complete medium was added prior to exposure to
the drugs for the concentration and time indicated at 37 8C and
6% CO2 without or with exposure to a static magnetic field. The
magnetic field exposure was obtained by incubating the cells in
the cell culture incubator onto 48 magnets inserted into the wells
of a 48-well plate. Cylindrical (10 mm diameter, 5 mm height)
NdFeB/N35 neodymium-boron-iron permanent magnets, magne-
tized axially and coated with Ni (Maurer Magnetic, Grçningen, Swit-
zerland) were used (remanence, Br=1.2 T). Under this experimental
setting, the cell layer is located ~2 mm from the magnets and the
upper layer of the culture medium containing the CPT–USPIOs is
located 6 mm away from the magnet. At the level of cells (~2 mm
from the surface of the magnets) a magnetic flux density of
265 mT and a field gradient of 72 Tm1 was induced (calculated
using vizimag 3.5, http://www.vizimag.com). In order to obtain
almost identical magnetic field conditions, the external wells of the
cell plate were not used. After the incubation period, the cell
layers were treated as above.
Calculation of results : Each experiment was repeated in triplicate
wells at least twice. Means and standard deviation were calculated.
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